Dr. Laura Sepp-Lorenzino joins Lexeo Therapeutics (LXEO) board and science committee
Rhea-AI Filing Summary
Lexeo Therapeutics, Inc. appointed Dr. Laura Sepp-Lorenzino to its board of directors effective April 28, 2026. She will serve until the company’s 2028 annual meeting of stockholders and has also been named to the company’s Science and Technology Committee.
Dr. Sepp-Lorenzino brings extensive experience from leadership and scientific roles at multiple biotechnology and pharmaceutical companies and currently leads a consulting firm focused on genomic medicine. Under Lexeo’s non-employee director compensation policy, she will receive $40,000 in annual cash compensation and an initial option to purchase 50,000 shares, with future annual option grants of 25,000 shares beginning with the 2027 annual meeting.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
1 item
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Key Figures
Appointment date: April 28, 2026
Board term end: 2028 annual meeting
Annual cash compensation: $40,000
+3 more
6 metrics
Appointment date
April 28, 2026
Effective date of Dr. Sepp-Lorenzino’s board appointment
Board term end
2028 annual meeting
Scheduled expiration of director term
Annual cash compensation
$40,000
Yearly cash fee for non-employee board service
Initial stock option grant
50,000 shares
Option award granted on appointment date
Annual option grant
25,000 shares
Expected yearly option grant starting with 2027 annual meeting
Director age
65
Age of Dr. Sepp-Lorenzino at appointment
Key Terms
Non-Employee Director Compensation Policy, indemnification agreement, Item 404(a) of Regulation S-K, Science and Technology Committee, +1 more
5 terms
Non-Employee Director Compensation Policy financial
"In accordance with the Company’s Non-Employee Director Compensation Policy (the “Director Compensation Policy”)"
indemnification agreement regulatory
"The Company has entered into its standard form of indemnification agreement with Dr. Sepp-Lorenzino"
An indemnification agreement is a contract in which one party promises to cover losses, costs, or legal claims that another party might face, acting like a tailored safety net or private insurance policy. For investors, it matters because such agreements shift potential financial risk away from a company or its officers and onto the indemnifier, which can affect a company’s future liabilities, cash flow and how risky the investment appears during deal-making or litigation.
Item 404(a) of Regulation S-K regulatory
"any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K"
Science and Technology Committee financial
"appointed Dr. Sepp-Lorenzino as a member of the Company's Science and Technology Committee"
Annual Grant financial
"including an annual option to purchase 25,000 shares, effective on the date of each annual meeting of the stockholders (the “Annual Grant”)"
FAQ
What did Lexeo Therapeutics (LXEO) announce in this 8-K filing?
Lexeo Therapeutics announced the appointment of Dr. Laura Sepp-Lorenzino to its board of directors, effective April 28, 2026. She will serve until the 2028 annual meeting and join the Science and Technology Committee, bringing extensive genomic medicine and biopharmaceutical leadership experience.
Who is Dr. Laura Sepp-Lorenzino, the new Lexeo Therapeutics (LXEO) director?
Dr. Laura Sepp-Lorenzino is a biochemist and industry leader who has held senior roles at Intellia Therapeutics, Vertex Pharmaceuticals, Alnylam Pharmaceuticals, and Merck. She now leads GNMmeds LLC and serves on several biotech boards, adding deep genomic medicine and RNA therapeutics expertise to Lexeo.
What compensation will Dr. Sepp-Lorenzino receive as a Lexeo Therapeutics (LXEO) director?
Under Lexeo’s non-employee director compensation policy, Dr. Sepp-Lorenzino will receive $40,000 in annual cash compensation for board service. She also received an initial stock option for 50,000 shares and is eligible for future annual option grants of 25,000 shares, subject to policy terms.
When will Dr. Sepp-Lorenzino receive annual equity grants from Lexeo Therapeutics (LXEO)?
Annual option grants of 25,000 shares begin with the 2027 annual meeting of stockholders. Because her appointment date is within six months of the 2026 annual meeting, the policy makes her ineligible for an annual grant tied to the 2026 meeting, delaying recurring awards until 2027.
Are there special arrangements behind Dr. Sepp-Lorenzino’s appointment to Lexeo Therapeutics (LXEO)?
Lexeo states there are no arrangements or understandings with any persons under which Dr. Sepp-Lorenzino was appointed as director, and no family relationships with existing directors or executive officers. This indicates a standard, independent board appointment process consistent with typical corporate governance practice.
AI-generated analysis. How Rhea-AI works. Not financial advice.
